Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 08, 2025
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited held its 47th AGM on August 8, 2025 via video conferencing, with 65 members present. A total of 18 resolutions were tabled and decided through an electronic poll (Insta Poll). Key items included adoption of FY25 audited financial statements, declaration of a final dividend of 10% (Re. 0.50 per equity share) for FY ending March 31, 2025, and re-appointment of Prof. Ravi Rasendra Mazumdar as a director liable to retire by rotation. Re-appointment of Naina Lal Kidwai as Independent Director and approval for payment of director remuneration in case of inadequate profits were passed as special resolutions. Multiple material related party transactions between group subsidiaries (Biocon Biologics, Biosimilars Newco, Biocon Sdn. Bhd., etc.) were approved. Statutory auditors BSR & Co. LLP and secretarial auditors V. Sreedharan & Associates issued unqualified opinions on FY25 reports. Voting results will be filed with stock exchanges within 2 working days.
This is a routine regulatory disclosure of AGM proceedings. The final dividend of Re. 0.50 per share is a positive cash-return signal for shareholders. No material surprises were flagged; approval of inter-group related party transactions is normal given Biocon's complex subsidiary structure. Actual voting outcomes on each resolution are still awaited.